September meeting info for idiots who cant read or acknowledge potential.
Professor Poon's presentation will include the most recent overall survival data. Recent HEAT Study post-hoc analysis, strongly suggest positive progression-free survival (PFS) and overall survival (OS) in ThermoDoxÂ® treated patients when heating cycles from the radiofrequency ablation (RFA) procedure were optimized. undergo RFA for 45 minutes or more. These findings apply to single HCC lesions (63% of the HEAT Study population) from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent approximately 300 patients.
-- Celsion is sponsoring a symposium in conjunction with the ILCA conference moderated by Professor Riccardo Lencioni, MD, FSIR, EBIR, the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy. Participants will include Professor Josep Llovet, MD, PhD, Professor of Medicine and Director, Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine; Ghassan K. Abou-Alfa MD, PhD, Associate Attending Memorial Sloan-Kettering Cancer Center, New York, NY, Associate Professor, Weill Medical College at Cornell University, New York, NY, and Associate Professor, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY ; and Professor Ronnie Poon, MD, PhD. The discussion will focus on a review of new developments in the treatment of early-intermediate HCC and discuss updated data from the HEAT Study post-hoc analysis. The Company will also have an Exhibit Booth (#2) at the ILCA conference to meet with attendees.
1) Latest OS data, which means "new" data you jackwagons.
2) The list of professionals,(i.e. PHD's attending) has increased with new HIGHLY respected members of the HCC field. Remember the a-holes who were making fun of CLSN's in house medical staff?
With CLSN getting backed by the best in the business hopefully it will bode well wtih the FDA and more importantly Hinsun and the CFDA.
"As we continue to follow patients in the HEAT Study to the secondary endpoint, Overall Survival, there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys, Celsion's Chief Medical Officer. "It is impressive that a single dose of ThermoDox® can demonstrate a meaningful impact on patient survival. The influence of longer RFA heating time on local tissue concentration is consistent with the mechanism of ThermoDox® activity."